论文部分内容阅读
目的:评价重组人血管内皮抑制素与培美曲塞对肺腺癌患者的疗效及其血管内皮生长因子(VEGF)和T-细胞亚群水平的影响。方法:选取2015年10月—2016年12月间收治的肺腺癌患者90例临床资料,采用随机分组法将其分为观察组(45例)和对照组(45例);对照组患者给予培美曲塞治疗,观察组患者在对照组基础上加用重组人血管内皮抑制素治疗,比较两组患者治疗后的总有效率和治疗前后血清VEGF及T-细胞亚群(CD4+、CD8+、CD4+/CD8+)测得值的变化情况。结果:观察组患者治疗后的总有效率为86.67%高于对照组为60.00%(P<0.05);两组患者治疗前后血清VEGF水平显著改善,观察组治疗后血清VEGF水平低于对照组(P<0.05);两组患者治疗前后CD4+、CD4+/CD8+测得值显著改善,观察组患者治疗后CD4+、CD4+/CD8+测得值高于对照组(P<0.05)。结论:重组人血管内皮抑制素与培美曲塞联用治疗肺腺癌患者的临床疗效较好,显著改善了血清中VEGF和T-细胞亚群水平。
Objective: To evaluate the effect of recombinant human endostatin and pemetrexed on the efficacy and the level of vascular endothelial growth factor (VEGF) and T-cell subsets in patients with lung adenocarcinoma. Methods: The clinical data of 90 patients with lung adenocarcinoma admitted from October 2015 to December 2016 were selected and divided into observation group (45 cases) and control group (45 cases) by random grouping method. Patients in control group Pemetrexed treatment. The patients in the observation group were treated with recombinant human endostatin on the basis of the control group. The total effective rate and the levels of serum VEGF and T-cell subsets (CD4 +, CD8 + CD4 + / CD8 +) measured value changes. Results: The total effective rate after treatment in the observation group was 86.67%, which was significantly higher than that in the control group (60.00%, P <0.05). The serum VEGF levels in both groups were significantly improved before and after treatment. The serum VEGF levels in the observation group were lower than those in the control group P <0.05). The measured values of CD4 + and CD4 + / CD8 + before and after treatment in both groups were significantly improved. The measured values of CD4 + and CD4 + / CD8 + in the two groups were significantly higher than those in the control group after treatment (P <0.05). Conclusion: The combination of recombinant human endostatin and pemetrexed has a good clinical curative effect in patients with lung adenocarcinoma, and significantly improves the level of serum VEGF and T-cell subsets.